Alert: We're here for you. Learn how COVID-19 may affect mesothelioma patients.

miRview Meso Test

Fact Checked

Early detection of mesothelioma cancer is one of the keys to surviving it, making a novel diagnostic tool like the miRview meso test so important to the future goal of finding a cure.

Jump to a Topic:

The miRview meso test, developed by Rosetta Genomics in Philadelphia, involves a minimally invasive procedure that helps medical professionals to make the tough differentiation between malignant pleural mesothelioma and lung cancer.

It eventually could help patients shortcut the often lengthy and laborious process of getting a definitive diagnosis of mesothelioma, allowing them to begin treatment sooner, possibly before the disease has metastasized.

For now, though, it is used mostly in the courtroom by defendants and insurance companies in asbestos litigation cases to differentiate between mesothelioma cancer and other diseases with similar symptoms. Rosetta Genomics signed an agreement in 2011 with PACE Claims Services to market it worldwide for legal purposes.

The test has been used to rule out mesothelioma in patients who were exposed to asbestos – the cause of the cancer – and diagnosed with other lung or pleural tumors.

Avoid a Lengthy and Uncertain Wait

An accurate diagnosis of mesothelioma continues to be a challenge that may require chest X-rays, CT scans, MRIs, biopsies and more, and still leave questions unanswered.

miRview Biopsy

The miRview meso test has begun to eliminate some of the guesswork, using the latest, highly sensitive technology to measure the microRNA in a sample tissue obtained from a tumor biopsy. It measures the expression level of three specific biomarkers, including two carcinoma markers.

miRview Meso Test Sensitivity

According to a study published in the Journal of Molecular Diagnostics in September 2010, the miRview meso test had a sensitivity of 100 percent and a specificity of 94 percent when differentiating mesothelioma from other cancers of the lungs or pleura.

MicroRNAs are smaller, more precise regulators of other genes than the more accepted messenger RNA. MicroRNAs, which were discovered only in recent years, have proven to be highly effective biomarkers. They are exceptionally stable, allowing them to be preserved with routine methods for biopsies. They can help doctors identify cancers, guide therapy strategies and predict outcomes. Scientists now believe that controlling levels of specific microRNAs can slow cancer growth.

Doctor talking to patients

Connect with a Top Mesothelioma Doctor

We've helped thousands of people affected by mesothelioma find the best treatments.

Get Started Now

Early Diagnosis Is Key

The earlier that mesothelioma is diagnosed, the more treatment options there are — and the greater the chances of survival. One of the biggest problems with diagnosing mesothelioma is that early symptoms often mimic those of less serious illnesses, which slows the process.

Thoracoscopies are considered the most accurate way to diagnosis mesothelioma. They involve a biopsy sample taken with a camera-equipped tube that goes through the chest wall. Because they are complex procedures, doctors don’t often take them unless there are significant signs from less invasive tests. This method allows a good view of the pleural cavity and provides a sample.

Quick Fact:

The miRview meso test, along with scans and imaging tests, can prompt a doctor to order the more aggressive thoracoscopy.

Proven Accuracy

Researchers from the MD Anderson Comprehensive Cancer Center (MDACC) in Texas presented a study of the miRview meso test at the 2010 American Society for Clinical Oncology Convention, giving it a stamp of approval.

The miRview meso test, like others involving biomarkers, has proven to be effective in determining the progression of mesothelioma and its aggressiveness. It can help a doctor in prescribing a treatment plan.

Rosetta Genomics is a developer of micro-RNA diagnostic tests and therapeutic tools. There are miRview tests that help with various cancers, including identifying subtypes of lung cancer and kidney tumors. Rosetta Genomics estimates that in the United States, 200,000 patients each year may benefit from miRview tests.

Kenneth Berlin President and CEO of Rosetta Genomics

“The performance of our miRview test, as validated by the MDA clinicians, matched the results we achieved in our validation study … and demonstrates how well the test performed in the ‘real world clinical setting,’ The results of this study are a testament to the overall scientific strength of Rosetta’s microRNA platform technology.”

The miRview meso test is widely available. Most oncologists who have dealt with mesothelioma, lung cancer or other thoracic cancers will be familiar with this procedure. Doctors can order collection kits, sample preparation instructions and shipping instructions from the company by phone or online.

A biopsy tissue sample for the test can be obtained during an office visit. The sample can be with an unstained slide, or a tumor section. It is sent to the Rosetta lab for state-of-the-art analysis. Within 10 days, the report is returned to your doctor.

Get the Compensation You Deserve

File a Claim Mesothelioma Packet

Learn About Top Mesothelioma Treatments

Get Your Guide

Immunotherapy & Mesothelioma Clinical Trials

Find Treatment

Registered Nurse and Patient Advocate

Karen Selby joined in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at
Edited by
Reviewed by placeholder
Medical Review By

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Press Release. (7 July 2010). Rosetta Genomics, Ltd. Data Presented at ASCO 2010 by M.D. Anderson researchers demonstrate the ability of miRview meso test to identify the most likely origin of metastases in cancer of unknown primary. Retrieved from:
  2. Company Overview. Rosetta Genomics. (2013). Retrieved from:
  3. News & Events Press Release. (14 June 2011). Rosetta Genomics Signs Marketing Agreement with PACE Claim Services for miRview meso. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified October 7, 2020

Chat live with a patient advocate now